Skip to content
← All settings

DISEASE & TREATMENT SETTING

JAYPIRCA: refractory Chronic Lymphocytic Leukemia

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.

Broader topic: Chronic Lymphocytic Leukemia

Source population
Not part of this definition
Disease extent
refractory
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from the FDA approved indication for JAYPIRCA (product label). Only dimensions stated in that wording are part of this definition.
      source wording
      1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.

      Study evidence for this setting

      59 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00040846 · Registry condition search · Scope: unclear

      Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

      5 outcome links · 6 safety-group records · 0 quality-of-life measures

      →

      NCT00049504 · Registry condition search · Scope: unclear

      Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

      3 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00058240 · Registry condition search · Scope: unclear

      Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

      3 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00075478 · Registry condition search · Scope: unclear

      Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00089011 · Registry condition search · Scope: unclear

      Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00089076 · Registry condition search · Scope: unclear

      MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00105001 · Registry condition search · Scope: unclear

      Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog

      5 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT00118352 · Registry condition search · Scope: unclear

      Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant

      6 outcome links · 3 safety-group records · 0 quality-of-life measures

      →

      NCT00119392 · Registry condition search · Scope: unclear

      Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00288067 · Registry condition search · Scope: unclear

      Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

      2 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00290472 · Registry condition search · Scope: unclear

      CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

      3 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00309842 · Registry condition search · Scope: unclear

      Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00387426 · Registry condition search · Scope: unclear

      Sunitinib in Treating Patients With Idiopathic Myelofibrosis

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00408681 · Registry condition search · Scope: unclear

      Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00536601 · Registry condition search · Scope: unclear

      High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

      4 outcome links · 5 safety-group records · 0 quality-of-life measures

      →

      NCT00648739 · Registry condition search · Scope: unclear

      Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

      6 outcome links · 7 safety-group records · 0 quality-of-life measures

      →

      NCT00711828 · Registry condition search · Scope: unclear

      Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00719888 · Registry condition search · Scope: unclear

      Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00723099 · Registry condition search · Scope: unclear

      Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00789776 · Registry condition search · Scope: unclear

      Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolim

      6 outcome links · 2 safety-group records · 1 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice